Table 1.

Review of intraperitoneal chemotherapy trials in primary ovarian cancer.

Study (Level of Evidence)	Cohorts	Drugs	Results
Ansaloni, 2012, Level II [30]	Open, prospective, nonrandomized phase II study in patients with primary or recurrent peritoneal carcinomatosis with ovarian cancer ● Primary (n = 9) ● Recurrent (n = 30)	● Cisplatin 100 mg/m2 ● Paclitaxel 175 mg/m2 ● Doxorubicin 35 mg/m2 ● 90 min at 41.5 °C Agent(s) determined based on prior systemic chemotherapy that had been received. 66% received cisplatin + doxorubicin.	● CC-0 (complete cytoreduction score-0) achieved in 90% ● Mean hospital stay 23.8 days ● One postoperative death ● No significant differences in 5 year survival in primary ovarian cancer cohort
Lim, 2017, Level I [35]	Randomized controlled trial in primary ovarian cancer staged III and IV ● HIPEC + Cytoreductive surgery (CRS) + Systemic chemotherapy (CT) (n = 92) ● CRS + Systemic CT (n = 92)	● Cisplatin 75 mg/m2 ● 90 min at 41.5 °C	5 year progression-free survival (p = 0.569) ● HIPEC: 20.9% ● Control: 16% Five year overall survival (p = 0.574) ● HIPEC: 51% ● Control: 49.4% No statistical difference in morbidities between groups
Van Driel, 2018, Level I [34]	Multicenter prospective randomized controlled phase III trial Stage III ovarian cancer who had received neoadjuvant IV chemotherapy with carboplatin and paclitaxel with stable disease after 3 cycles. ● CRS + HIPEC ● CRS alone	● Cisplatin 100 mg/m2 ● 90 min at 40 °C	Primary end point: progression-free survival ● HIPEC: 14.2 months ● Control: 10.7 months Median overall survival ● HIPEC: 45.7 months ● Control: 33.9 months Adverse events of grade 3 and 4: 25% and 27%